# Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-participation-in-upcoming-investor-conferences Ticker: ABEO Company: Abeona Therapeutics Source: Abeona Therapeutics Published: 2026-06-25 13:46 EST Original Source URL: https://investors.abeonatherapeutics.com ## Summary CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team…... ## Article Body May 26, 2026 8:30am EDT CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies Global Healthcare Conference: Fireside chat at 3:10 PM ET on Thursday, June 4, 2026 and investor meetings. Goldman Sachs 47 th Annual Global Healthcare Conference 2026: Investor meetings on Monday, June 8, 2026. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the event will also be available for a limited time. About Abeona Therapeutics Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN ® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com . ZEVASKYN ® , Abeona Assist™, Abeona Therapeutics ® , and their related logos are trademarks of Abeona Therapeutics Inc. Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com Source: Abeona Therapeutics Inc. Released May 26, 2026 ## Recent Company News - 2026-07-01 11:30 EST — [Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-68d0b897) — Source: Abeona Therapeutics - 2026-06-25 13:46 EST — [Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-participation-in-upcoming-investor-conferences) — Source: Abeona Therapeutics - 2026-06-25 13:46 EST — [Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update](https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-reports-first-quarter-2026-results-and-provides-pipeline-update) — Source: Abeona Therapeutics - 2026-06-25 13:46 EST — [Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-activation-of-children-s-hospital-of-philadelphia-as-a-new-qualified-treatment-center-for-zevaskynr) — Source: Abeona Therapeutics - 2026-06-25 13:46 EST — [Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program](https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-abo-503-gene-therapy-for-x-linked-retinoschisis-xlrs-selected-by-fda-for-rare-disease-endpoint-advancement-rdea-pilot-program) — Source: Abeona Therapeutics ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)